During the last session, BriaCell Therapeutics Corp (NASDAQ:BCTX)’s traded shares were 2.06 million, with the beta value of the company hitting 1.12. At the end of the trading day, the stock’s price was $2.07, reflecting an intraday loss of -1.90% or -$0.04. The 52-week high for the BCTX share is $29.40, that puts it down -1320.29 from that peak though still a striking 0.97% gain since the share price plummeted to a 52-week low of $2.05. The company’s market capitalization is $14.03M, and the average intraday trading volume over the past 10 days was 1.34 million shares, and the average trade volume was 1.73 million shares over the past three months.
BriaCell Therapeutics Corp (NASDAQ:BCTX) trade information
BriaCell Therapeutics Corp (BCTX) registered a -1.90% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.90% in intraday trading to $2.07, hitting a weekly high. The stock’s 5-day price performance is -29.35%, and it has moved by -40.52% in 30 days. Based on these gigs, the overall price performance for the year is -75.58%. The short interest in BriaCell Therapeutics Corp (NASDAQ:BCTX) is 0.21 million shares and it means that shorts have 0.31 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 47.85%. While earnings are projected to return 41.56% in 2025, the next five years will return 31.60% per annum.
BCTX Dividends
BriaCell Therapeutics Corp is due to release its next quarterly earnings on 2025-Jun-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BriaCell Therapeutics Corp (NASDAQ:BCTX)’s Major holders
BriaCell Therapeutics Corp insiders own 7.33% of total outstanding shares while institutional holders control 10.88%, with the float percentage being 11.74%.
Data provided on Mar 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 481.0 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $995.0 market value.